The Prevalence of CYP2C19 Polymorphism in Patients with Symptomatic Intracranial Atherosclerosis.

IF 2 Q3 PERIPHERAL VASCULAR DISEASE Cerebrovascular Diseases Extra Pub Date : 2025-01-02 DOI:10.1159/000543331

Songchai Kittipanprayoon, Pongpat Vorasayan, Aurauma Chutinet, Pajaree Chariyavilaskul, Nijasri C Suwanwela

{"title":"The Prevalence of CYP2C19 Polymorphism in Patients with Symptomatic Intracranial Atherosclerosis.","authors":"Songchai Kittipanprayoon, Pongpat Vorasayan, Aurauma Chutinet, Pajaree Chariyavilaskul, Nijasri C Suwanwela","doi":"10.1159/000543331","DOIUrl":null,"url":null,"abstract":"Introduction: Combination of clopidogrel and aspirin has been proven beneficial in treating symptomatic intracranial stenosis. The CYP2C19 polymorphism (CYP2C19*1, CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles) affects the efficacy of clopidogrel. Although epidemiologic studies of CYP2C19 polymorphism have been conducted in the Thai population, data on the frequency of allelic variants of CYP2C19 in Thai patients with symptomatic intracranial stenosis are lacking. This study aims to determine the prevalence of CYP2C19 polymorphism in patients with symptomatic intracranial stenosis.Methods: The study included 100 Thai patients with symptomatic intracranial stenosis. Genotyping of CYP2C19 alleles (CYP2C19*1, CYP2C19*2, CYP2C19*3, and CYP2C19*17) was performed using the Real-time Polymerase Chain Reaction (rt-PCR) technique.Results: The allele frequencies of CYP2C19*1, CYP2C19*2, CYP2C19*3, and CYP2C19*17 were 70.5%, 26%, 2.5%, and 1%, respectively. The results indicated that 53% of patients with symptomatic intracranial stenosis were normal metabolizers, while 36% were intermediate metabolizers and 10% were poor metabolizers.Conclusion: Almost half of the Thai patients with symptomatic intracranial stenosis were intermediate or poor metabolizers. The combination of aspirin and clopidogrel might not be effective in this group of patients.","PeriodicalId":45709,"journal":{"name":"Cerebrovascular Diseases Extra","volume":" ","pages":"1-12"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cerebrovascular Diseases Extra","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000543331","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Combination of clopidogrel and aspirin has been proven beneficial in treating symptomatic intracranial stenosis. The CYP2C19 polymorphism (CYP2C19*1, CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles) affects the efficacy of clopidogrel. Although epidemiologic studies of CYP2C19 polymorphism have been conducted in the Thai population, data on the frequency of allelic variants of CYP2C19 in Thai patients with symptomatic intracranial stenosis are lacking. This study aims to determine the prevalence of CYP2C19 polymorphism in patients with symptomatic intracranial stenosis.

Methods: The study included 100 Thai patients with symptomatic intracranial stenosis. Genotyping of CYP2C19 alleles (CYP2C19*1, CYP2C19*2, CYP2C19*3, and CYP2C19*17) was performed using the Real-time Polymerase Chain Reaction (rt-PCR) technique.

Results: The allele frequencies of CYP2C19*1, CYP2C19*2, CYP2C19*3, and CYP2C19*17 were 70.5%, 26%, 2.5%, and 1%, respectively. The results indicated that 53% of patients with symptomatic intracranial stenosis were normal metabolizers, while 36% were intermediate metabolizers and 10% were poor metabolizers.

Conclusion: Almost half of the Thai patients with symptomatic intracranial stenosis were intermediate or poor metabolizers. The combination of aspirin and clopidogrel might not be effective in this group of patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

CYP2C19多态性在症状性颅内动脉粥样硬化患者中的患病率

氯吡格雷联合阿司匹林治疗症状性颅内狭窄已被证明是有益的。CYP2C19多态性（CYP2C19*1、CYP2C19*2、CYP2C19*3、CYP2C19*17等位基因）影响氯吡格雷的疗效。尽管在泰国人群中进行了CYP2C19多态性的流行病学研究，但缺乏泰国症状性颅内狭窄患者CYP2C19等位基因变异频率的数据。本研究旨在确定CYP2C19多态性在症状性颅内狭窄患者中的患病率。方法：研究纳入100例泰国症状性颅内狭窄患者。采用实时聚合酶链式反应（rt-PCR）技术对CYP2C19等位基因（CYP2C19*1、CYP2C19*2、CYP2C19*3、CYP2C19*17）进行分型。结果：CYP2C19*1、CYP2C19*2、CYP2C19*3、CYP2C19*17等位基因频率分别为70.5%、26%、2.5%、1%。结果显示，有症状的颅内狭窄患者中，正常代谢者占53%，中间代谢者占36%，差代谢者占10%。结论：几乎一半的泰国症状性颅内狭窄患者是中度或低代谢。阿司匹林和氯吡格雷联用可能对这组患者无效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cerebrovascular Diseases Extra PERIPHERAL VASCULAR DISEASE-

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： This open access and online-only journal publishes original articles covering the entire spectrum of stroke and cerebrovascular research, drawing from a variety of specialties such as neurology, internal medicine, surgery, radiology, epidemiology, cardiology, hematology, psychology and rehabilitation. Offering an international forum, it meets the growing need for sophisticated, up-to-date scientific information on clinical data, diagnostic testing, and therapeutic issues. The journal publishes original contributions, reviews of selected topics as well as clinical investigative studies. All aspects related to clinical advances are considered, while purely experimental work appears only if directly relevant to clinical issues. Cerebrovascular Diseases Extra provides additional contents based on reviewed and accepted submissions to the main journal Cerebrovascular Diseases.